[go: up one dir, main page]

MX2017003014A - Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. - Google Patents

Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.

Info

Publication number
MX2017003014A
MX2017003014A MX2017003014A MX2017003014A MX2017003014A MX 2017003014 A MX2017003014 A MX 2017003014A MX 2017003014 A MX2017003014 A MX 2017003014A MX 2017003014 A MX2017003014 A MX 2017003014A MX 2017003014 A MX2017003014 A MX 2017003014A
Authority
MX
Mexico
Prior art keywords
antibodies
beta
alpha
humanized anti
disclosed
Prior art date
Application number
MX2017003014A
Other languages
English (en)
Inventor
Qian Fang
M Violette Shelia
Owen CAMERON Thomas
Adam CRACKOWER Michael
M Dolinski Brian
J M Hanf Karl
Theresa MCCURLEY Amy
PREYER Martin
Henry WEINREB Paul
Eric Pederson Nels
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2017003014A publication Critical patent/MX2017003014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen anticuerpos y fragmentos de anticuerpos humanizados que se unen a la avb5. También se describen métodos de uso de los anticuerpos y fragmentos de anticuerpos descritos para tratar o prevenir enfermedades mediadas por la avb5.
MX2017003014A 2014-09-12 2015-09-11 Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. MX2017003014A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049987P 2014-09-12 2014-09-12
PCT/US2015/049746 WO2016040839A1 (en) 2014-09-12 2015-09-11 Humanized anti-alpha v beta 5 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2017003014A true MX2017003014A (es) 2017-05-30

Family

ID=54150752

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003014A MX2017003014A (es) 2014-09-12 2015-09-11 Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.

Country Status (9)

Country Link
US (1) US20170362324A1 (es)
EP (1) EP3191519A1 (es)
JP (1) JP2017534252A (es)
CN (1) CN107001469A (es)
AU (1) AU2015314809A1 (es)
CA (1) CA2959772A1 (es)
MA (1) MA40536A (es)
MX (1) MX2017003014A (es)
WO (1) WO2016040839A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010275367B2 (en) * 2009-07-24 2015-09-03 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avB5 integrin
ES3023938T3 (en) 2016-09-29 2025-06-03 Univ California Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy
US20210070860A1 (en) * 2018-03-21 2021-03-11 Dana-Farber Cancer Institute, Inc. Fc variant compositions and methods of use thereof
JP2022527372A (ja) * 2019-04-08 2022-06-01 バイオジェン・エムエイ・インコーポレイテッド 抗インテグリン抗体及びそれらの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053041B1 (en) * 1996-05-31 2006-05-30 The Scripps Research Institute Methods and compositions useful for inhibition of αvβ5mediated angiogenesis
EP0907661A4 (en) * 1996-05-31 2000-07-26 Scripps Research Inst METHODS AND COMPOSITIONS FOR INHIBITING ALPHA-V-BETA5 MEDIATED ANGIOGENESIS.
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
CN1964740A (zh) * 2004-04-02 2007-05-16 加利福尼亚大学董事会 治疗和预防与αVβ5整联蛋白有关的疾病的方法和组合物
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
AU2010275367B2 (en) * 2009-07-24 2015-09-03 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avB5 integrin
EP2608804A4 (en) * 2010-08-27 2015-03-11 Univ Miami TREATMENT OF KIDNEY DISEASES
US9492563B2 (en) * 2012-10-30 2016-11-15 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use

Also Published As

Publication number Publication date
US20170362324A1 (en) 2017-12-21
CA2959772A1 (en) 2016-03-17
JP2017534252A (ja) 2017-11-24
CN107001469A (zh) 2017-08-01
WO2016040839A1 (en) 2016-03-17
EP3191519A1 (en) 2017-07-19
AU2015314809A1 (en) 2017-03-16
MA40536A (fr) 2016-03-17

Similar Documents

Publication Publication Date Title
ZA201708265B (en) Tigit-binding agents and uses thereof
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
MX2022014764A (es) Anticuerpos biespecificos contra beta amiloide humana/receptor de transferrina humano y metodos de uso.
PH12016501644B1 (en) Binding proteins and methods of use thereof
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
SG10201901057UA (en) Anti-pd-l1 antibodies
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
PH12018501177B1 (en) Antibodies targeting fc receptor-like 5 and methods of use
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
EA201790342A1 (ru) Антитела к trem2 и способы их применения
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
PH12016501366A1 (en) Novel anti-baff antibodies
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
HK1219740A1 (zh) 使用抗αVβ5抗体治疗和预防急性肾损伤
PH12017501522A1 (en) Antibodies to tau and uses thereof
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
IL268007A (en) Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
WO2014143739A3 (en) Anti-alpha v beta 6 antibodies and uses thereof
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
WO2014144616A3 (en) Anti-alpha v beta 5 antibodies and uses thereof